cbp-307
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2014 (NCT02280434)
Timeline
Indications
Mechanism of action
- Sphingosine 1-phosphate receptor 1INHIBITOR
S1PR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cbp-307
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05040113 | Phase 1 | Sep 4, 2021 | Suzhou Connect Biopharmaceuticals |
| NCT04818229 | Phase 1 | Jun 1, 2021 | Suzhou Connect Biopharmaceuticals |
| NCT04700449 | Phase 2 | Feb 27, 2019 | Suzhou Connect Biopharmaceuticals |
| NCT02280434 | Phase 1 | Nov 1, 2014 | Nucleus Network Ltd, Suzhou Connect Biopharmaceuticals, Tigermed Consulting Co., Ltd |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Connect Biopharmaceuticals | For profit | 4 | 4 | 2 | 2014 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2014 |
| Tigermed Consulting Co., Ltd | For profit | 1 | 0 | 1 | 2014 |
3 organizations
Page 1 / 1